Changes in serum and salivary amylase during radiotherapy for head and neck cancer: a comparison of conventionally fractionated radiotherapy with CHART
- PMID: 1377830
- DOI: 10.1016/0167-8140(92)90350-4
Changes in serum and salivary amylase during radiotherapy for head and neck cancer: a comparison of conventionally fractionated radiotherapy with CHART
Abstract
The changes in serum amylase that occur when radiotherapy is given in the treatment of head and neck cancer has been studied in 41 patients, 29 treated by CHART and 12 by conventionally fractionated radiotherapy. The peak rise in serum amylase following the start of treatment is seen earlier and is greater in the patients receiving continuous hyperfractionated accelerated radiotherapy (CHART). The serum amylase returns to normal earlier in the CHART patients so that the area under the curve is the same for both groups. The difference probably reflects the more rapid delivery of treatment to the patients receiving CHART. A close correlation between the peak rise in serum amylase and the amount of parotid tissue in the treatment volume is demonstrated. For six patients the total amount of amylase secreted by the parotid gland during CHART was measured and found to decline rapidly within a few days of the start of radiotherapy. The rise in serum amylase that results from the irradiation of salivary tissue provides a unique biochemical measure of an early radiation effect in a normal tissue. This probably reflects the interphase cell death of serous salivary cells. Although these immediate changes are of considerable interest they may not relate to the late effects of radiation on salivary gland function.
Similar articles
-
The early changes in salivary gland function during and after radiotherapy given for head and neck cancer.Radiother Oncol. 1994 Jan;30(1):26-32. doi: 10.1016/0167-8140(94)90006-x. Radiother Oncol. 1994. PMID: 8153377 Clinical Trial.
-
Immunohistochemical and quantitative changes in salivary EGF, amylase and haptocorrin following radiotherapy for oral cancer.Acta Otolaryngol. 1996 Jan;116(1):137-43. doi: 10.3109/00016489609137727. Acta Otolaryngol. 1996. PMID: 8820365
-
Plasma amylase activity as a biochemical indicator of radiation injury to salivary glands.Acta Radiol Oncol. 1984;23(1):9-14. doi: 10.3109/02841868409135978. Acta Radiol Oncol. 1984. PMID: 6203336
-
Parotid gland function following accelerated and conventionally fractionated radiotherapy.Radiother Oncol. 1991 Oct;22(2):133-9. doi: 10.1016/0167-8140(91)90009-6. Radiother Oncol. 1991. PMID: 1957003 Review.
-
Xerostomia in head and neck malignancy.Oral Oncol. 2010 Jun;46(6):460-3. doi: 10.1016/j.oraloncology.2010.03.008. Epub 2010 Apr 18. Oral Oncol. 2010. PMID: 20403723 Review.
Cited by
-
Relationship between Salivary Amylase and Xerostomia in Intensity-Modulated Radiation Therapy for Head and Neck Cancer: A Prospective Pilot Study.Curr Oncol. 2022 Sep 15;29(9):6564-6572. doi: 10.3390/curroncol29090516. Curr Oncol. 2022. PMID: 36135085 Free PMC article.
-
Radiation therapy and serum salivary amylase in head and neck cancer.Oncotarget. 2017 Jun 28;8(52):90496-90500. doi: 10.18632/oncotarget.18763. eCollection 2017 Oct 27. Oncotarget. 2017. PMID: 29163848 Free PMC article. Review.
-
Are salivary amylase and pH - Prognostic indicators of cancers?J Oral Biol Craniofac Res. 2015 May-Aug;5(2):81-5. doi: 10.1016/j.jobcr.2015.04.002. Epub 2015 May 23. J Oral Biol Craniofac Res. 2015. PMID: 26258019 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
